According to this new study, the global genomics market is expected to reach $70.52 billion by 2031, rising at a strong CAGR of 11.1% between 2024 and 2031. This significant increase reflects the rapid integration of genetics into mainstream healthcare, pharmacological innovation, and scientific research.
- Market Overview & Growth Drivers
The growth of the genomics market is driven by several critical factors:
- Genetic and chronic diseases are becoming more prevalent.
- Increasing incorporation of genomic data into clinical workflows
- Surge in public and private investments in genomics research
- Decreasing costs of sequencing technologies
- Expanding use of genomics in personalized medicine and targeted therapies
However, challenges such as a lack of standardized approaches, concerns around data privacy, and a shortage of skilled personnel pose limitations to market expansion.
- Segment Insights
- Offering
The genomics market is segmented into instruments, consumables, software, and services. In 2024, consumables are expected to dominate due to their recurring use in genomic research and diagnostic processes, particularly in NGS workflows.
- Technology
Key technologies include sequencing (NGS and others), microarray, PCR, and nucleic acid extraction & purification. Sequencing technologies are forecasted to exhibit the highest CAGR during the forecast period, fueled by advancements in scalability, speed, and accuracy.
- Application
Applications span drug discovery & development, diagnostics, life science research, and others. Drug discovery & development is projected to grow fastest, supported by the rising demand for effective therapies for chronic diseases like cancer and diabetes.
- End Users
The primary end users are pharmaceutical & biotechnology companies, hospitals, diagnostic labs, CROs, and academic institutes. Pharmaceutical and biotech companies are set to hold the largest share in 2024, leveraging genomics for biomarker discovery, personalized medicine, and advanced research initiatives.
- Geographic Review: U.S. Leading Innovation
In 2024, North America, led by the U.S., is expected to dominate the global genomics market. The region benefits from significant R&D spending, high adoption of advanced healthcare technologies, strong academic-industrial collaborations, and a dense concentration of global players like Illumina, Thermo Fisher Scientific, and Bio-Rad.
Key innovation hubs in the U.S. include Boston, Silicon Valley, and San Diego, where investment in precision medicine and biotech continues to surge.
- Competitive Landscape & Key Players
The U.S. is home to several major players in the genomics space, including:
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Bio-Rad Laboratories, Inc.
- Agilent Technologies, Inc.
- Pacific Biosciences of California, Inc.
- Myriad Genetics, Inc.
Other influential players include QIAGEN (Netherlands), Oxford Nanopore (U.K.), and BGI Genomics (China).
Strategic moves such as M&A, product launches, and partnerships are common, as exemplified by Bio-Rad’s acquisition of Curiosity Diagnostics to enhance rapid PCR system development.
- Strategic Opportunities for Stakeholders
- Investment in NGS and software platforms for clinical genomics
- Expansion of personalized medicine pipelines through genomics-based biomarkers
- Data collaboration with academic and clinical institutions for population genomics
- Building workforce capabilities in bioinformatics and genomic analytics
- Future Outlook
Looking ahead, the genomics industry is poised to reshape healthcare through predictive diagnostics, digital health integration, and AI-driven genomic data interpretation. For C-suite decision-makers, the U.S. genomics market offers a ripe landscape for strategic investments, collaborations, and innovation acceleration.
Download the Sample Report to explore the full strategic insights and data forecasts:
???? Download Sample Report
For inquiries:
Meticulous Research®
Email- [email protected]
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research